Nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC), an enzyme that catalyzes the
conversion of guanosine-5′-triphosphate (GTP) to cyclic guanosine-3′, 5 …

Nitric oxide (NO) signaling represents one of the major regulatory pathways for
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …

Background and Aims HSCs and portal fibroblasts (PFs) are the major sources of collagen‐
producing myofibroblasts during liver fibrosis, depending on different etiologies. However …

Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …

Non-alcoholic steatohepatitis (NASH) is a chronic metabolic syndrome and the CFLAR-JNK
pathway can reverse the process of NASH. Although silibinin is used for the treatment of …

Increasing studies have identified the potential of mesenchymal stem cell-derived
extracellular vesicles (MSC-EVs) in non-alcoholic fatty liver disease (NAFLD) treatment …

Nonalcoholic fatty liver disease (NAFLD) with growing incidences is a major health concern
worldwide. Alteration in cellular redox homeostasis and autophagy plays a critical role in the …

Soluble guanylate cyclase (sGC) catalyzes the conversion of guanosine triphosphate into
cyclic guanosine-3′, 5′-monophosphate, a key second messenger in cell signaling and …

Intercellular crosstalk among various liver cells plays an important role in liver fibrosis,
cirrhosis, and hepatocellular carcinoma (HCC). Capillarization of liver sinusoidal endothelial …

Aims Maladaptive ventricular remodeling is a major cause of ventricular arrhythmias
following myocardial infarction (MI) and adversely impacts the quality of life of affected …